The startup develops targeted protein degradation therapeutics specifically for neuroblastoma, a cancer that primarily affects children. Their approach aims to enhance survival rates and improve the quality of life for pediatric patients by directly targeting the mechanisms driving tumor growth.
Funding
Funding not disclosed
Founders
Product
Problem
Neuroblastoma, a cancer primarily affecting children, has limited effective treatment options, leading to poor survival rates and diminished quality of life for pediatric patients. Current therapies often fail to specifically target the underlying mechanisms driving tumor growth, resulting in significant side effects and treatment resistance.
Solution
This startup is developing targeted protein degradation (TPD) therapeutics designed specifically for neuroblastoma. Their approach leverages small molecule degraders to selectively eliminate proteins critical for neuroblastoma cell survival and proliferation. By directly targeting these proteins, the therapeutics aim to disrupt the cancer's growth pathways, leading to tumor regression and improved patient outcomes. The TPD approach offers a more precise and potentially less toxic alternative to traditional chemotherapy, with the goal of enhancing survival rates and minimizing long-term side effects in pediatric neuroblastoma patients.
Target Audience
The primary target audience includes pediatric oncologists, hospitals specializing in pediatric cancer treatment, and pharmaceutical companies focused on developing novel cancer therapies.
Features
- Utilizes small molecule degraders to selectively target and eliminate proteins essential for neuroblastoma cell survival.
- Employs a rational drug design approach to optimize degrader specificity and efficacy.
- Focuses on proteins that are specifically overexpressed or mutated in neuroblastoma tumors.
- Aims to overcome drug resistance mechanisms commonly observed in neuroblastoma treatment.